Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
Type:
Grant
Filed:
July 23, 2014
Date of Patent:
June 7, 2016
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
Type:
Grant
Filed:
October 10, 2013
Date of Patent:
November 3, 2015
Assignee:
ISIS Pharmaceuticals Inc.
Inventors:
Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Brett Monia
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Grant
Filed:
January 5, 2012
Date of Patent:
October 29, 2013
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
Type:
Grant
Filed:
February 2, 2007
Date of Patent:
July 9, 2013
Assignees:
Merck Sharp & Dohme Corp., ISIS Pharmaceuticals, Inc.
Inventors:
Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Application
Filed:
January 5, 2012
Publication date:
January 3, 2013
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a TTC39 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL and/or decreasing PCSK9 in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate cardiovascular disease, or a symptom thereof.
Type:
Application
Filed:
September 24, 2010
Publication date:
October 25, 2012
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Rosanne M. Crooke, Mark Graham, Thomas A. Bell
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 7 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
Type:
Application
Filed:
July 15, 2010
Publication date:
August 23, 2012
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao
Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
Type:
Grant
Filed:
May 7, 2007
Date of Patent:
March 27, 2012
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Grant
Filed:
January 10, 2011
Date of Patent:
February 14, 2012
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Application
Filed:
March 9, 2011
Publication date:
October 6, 2011
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Michael T. Migawa, Xiaojing Wang, Eric E. Swayze, Richard H. Griffey
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Application
Filed:
January 10, 2011
Publication date:
July 7, 2011
Applicant:
ISIS Pharmaceuticals,Inc.
Inventors:
Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
Type:
Application
Filed:
April 10, 2006
Publication date:
June 9, 2011
Applicant:
ISIS Pharmaceuticals Inc.
Inventors:
Sanjay Bhanot, Brett P. Monia, John Geisler, Robert Mckay, Kenneth W. Dobie
Abstract: The present invention provides compounds and methods for modulating expression of a protein, including, but not limited to, modulating splicing of a pre-mRNA to modulate the amount of one or more variants of a protein.
Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Type:
Grant
Filed:
May 30, 2008
Date of Patent:
February 22, 2011
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
Type:
Application
Filed:
October 18, 2007
Publication date:
October 21, 2010
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Walter F. Lima, Timothy Vickers, Stanley T. Crooke
Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Type:
Application
Filed:
June 23, 2006
Publication date:
August 26, 2010
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Brenda F Baker, Adrian R. Krainer, Yimin Hua
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
Type:
Grant
Filed:
January 28, 2008
Date of Patent:
May 4, 2010
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
William Gaarde, Andrew T Watt, Brett P Monia, Mausumee Guha
Abstract: The present invention includes compositions and methods useful for modulating protein expression. In certain embodiments, the present invention includes oligomeric compounds comprising modified nucleosides and modified internucleoside linkages.
Type:
Application
Filed:
January 29, 2008
Publication date:
April 15, 2010
Applicant:
ISIS Pharmaceuticals, Inc
Inventors:
Balkrishen Bhat, Eric E. Swayze, Walter F. Lima, Stanley T. Crooke
Abstract: Provided herein is a method for reducing the amount of steroid required for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness, comprising administration of the steroid and an oligonucleotide targeted to IL-4R alpha. Also described is a method for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness comprising administration of a corticosteroid and an oligonucleotide targeted to IL-4R alpha. Further provided are compositions comprising a corticosteroid and an IL-4R alpha targeted antisense oligonucleotide.
Abstract: The present invention provides oligonucleotide primers and compositions and kits containing the same for rapid identification of bacteria by amplification of a segment of bacterial nucleic acid followed by molecular mass analysis.
Type:
Application
Filed:
February 17, 2005
Publication date:
February 11, 2010
Applicant:
ISIS Pharmaceuticals, Inc.
Inventors:
Rangarajan Sampath, Thomas A. Hall, David J. Ecker, Mark W. Eshoo, Christian Massire